Published in AIDS Weekly, December 21st, 1998
Combivir is a safe and effective, HIV compact formulation and could improve treatment adherence for HIV/AIDS patients requiring potent nucleoside analogue therapy, the companies say. Combivir is a fixed dose formulation combining two anti-HIV drugs, 3TC (lamivudine) and Retrovir (AZT/zidovudine), into one tablet. Taken twice daily, Combivir offers the advantage of reducing the number of tablets by up to six tablets per day or 2,190 tablets per year compared to the use of the two other...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.